TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors
Go back to TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 57.13 +0.23 (0.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $56.90 | 52 Week High | $77.12 | |||
| Open | $57.45 | 52 Week Low | $49.03 | |||
| Day High | $57.60 | P/E | 37.10 | |||
| Day Low | $56.77 | EPS | $1.54 | |||
| Volume | 7,839,148 | |||||
| (NASDAQ: TCRR) | Delayed: 1.48 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.48 | 52 Week High | $ | |||
| Open | $3.63 | 52 Week Low | $ | |||
| Day High | $1.48 | P/E | N/A | |||
| Day Low | $1.48 | EPS | $ | |||
| Volume | 52,452 | |||||
